Sigyn Therapeutics annual r&d spending
2020
2021
2022
2023
2024
Sigyn Therapeutics R&D Spending Growth & History (SIGY)
Sigyn Therapeutics's r&d spending was $773,279 for fiscal 2024.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $773,279 | −$24,886 | −3.12% |
| 2023 | 2023-12-31 | $798,165 | $140,508 | +21.36% |
| 2022 | 2022-12-31 | $657,657 | −$76,357 | −10.40% |
| 2021 | 2021-12-31 | $734,014 | $314,652 | +75.03% |
| 2020 | 2020-12-31 | $419,362 | — | — |
Sigyn Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $29,681 | −$176,480 | −85.60% |
| Q2 2025 | 2025-06-30 | $7,482 | −$232,947 | −96.89% |
| Q1 2025 | 2025-03-31 | $8,842 | −$223,751 | −96.20% |
| Q4 2024 | 2024-12-31 | $94,096 | −$121,837 | −56.42% |
| Q3 2024 | 2024-09-30 | $206,161 | −$9,069 | −4.21% |
| Q2 2024 | 2024-06-30 | $240,429 | $21,270 | +9.71% |
| Q1 2024 | 2024-03-31 | $232,593 | $84,750 | +57.32% |
| Q4 2023 | 2023-12-31 | $215,933 | $75,071 | +53.29% |
| Q2 2023 | 2023-09-30 | $215,230 | $81,460 | +60.90% |
| Q1 2023 | 2023-06-30 | $219,159 | $64,476 | +41.68% |
| Q4 2022 | 2023-03-31 | $147,843 | −$80,499 | −35.25% |
| Q4 2022 | 2022-12-31 | $140,862 | −$109,397 | −43.71% |
| Q3 2022 | 2022-09-30 | $133,770 | −$93,733 | −41.20% |
| Q2 2022 | 2022-06-30 | $154,683 | $14,947 | +10.70% |
| Q1 2022 | 2022-03-31 | $228,342 | $111,826 | +95.97% |
| Q4 2021 | 2021-12-31 | $250,259 | −$167,125 | −40.04% |
| Q3 2021 | 2021-09-30 | $227,503 | $227,503 | — |
| Q2 2021 | 2021-06-30 | $139,736 | $139,736 | — |
| Q1 2021 | 2021-03-31 | $116,516 | $114,538 | +5790.60% |
| Q4 2020 | 2020-12-31 | $417,384 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $1,978 | — | — |
Sigyn Therapeutics r&d spending trends
Between the periods ended 2020-12-31 and 2024-12-31, Sigyn Therapeutics's r&d spending increased from $419,362 to $773,279, a change of $353,917. The latest reported quarter, Q3 2025, shows $29,681.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics source filings ↗